What is Biolytic Lab Performance?
Biolytic Lab Performance, Inc. operates as a critical provider in the life sciences supply chain, specializing in the engineering and production of advanced DNA, RNA, and peptide oligonucleotide synthesizers. The company maintains a robust portfolio that spans low to high-throughput instrumentation, complemented by a comprehensive suite of synthesis consumables and essential laboratory accessories. Beyond hardware, the firm distinguishes itself through a service-oriented model that includes rigorous instrument qualification, technical training, and ongoing maintenance support. This integrated approach ensures that research institutions and commercial laboratories can maintain high-fidelity synthesis workflows, positioning Biolytic as a foundational partner for genomic and proteomic research initiatives globally.
How much funding has Biolytic Lab Performance raised?
Biolytic Lab Performance has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biolytic Lab Performance
PPP
Public-Private Partnership
What's next for Biolytic Lab Performance?
With this late-stage capital, Biolytic Lab Performance is well-positioned to expand its operational footprint and enhance its R&D pipeline for next-generation synthesis technology. The strategic focus will likely shift toward optimizing high-throughput automation to meet the increasing demand for synthetic biology applications. By leveraging this investment, the company aims to fortify its service infrastructure and broaden its market reach, ensuring that its oligonucleotide synthesis solutions remain at the forefront of scientific innovation. Future growth will be defined by the firm's ability to scale its manufacturing capacity while maintaining the precision and reliability required by its diverse client base in the global research community.
See full Biolytic Lab Performance company page
